News

Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients
New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...
MyChesCo on MSN1d
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial ...